Because reactive astrocytes and endothelial cells in the BBB in AD produce MMPs [28], prolonged activation of MMPs might lead to the degradation of CLDN-5 and, thus, lower plasma CLDN-5 levels in older compared with younger patients with cognitive deficits. This evidence concerns the gene CLDN5 and Alzheimer disease.